Sanctuary Advisors LLC Trims Stake in Halozyme Therapeutics, Inc. $HALO

Sanctuary Advisors LLC trimmed its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 56.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 12,907 shares of the biopharmaceutical company’s stock after selling 16,543 shares during the quarter. Sanctuary Advisors LLC’s holdings in Halozyme Therapeutics were worth $834,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in HALO. Measured Wealth Private Client Group LLC raised its holdings in shares of Halozyme Therapeutics by 51.5% in the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 124 shares in the last quarter. Abel Hall LLC grew its holdings in shares of Halozyme Therapeutics by 4.2% during the fourth quarter. Abel Hall LLC now owns 3,216 shares of the biopharmaceutical company’s stock worth $216,000 after purchasing an additional 129 shares in the last quarter. StoneX Group Inc. grew its holdings in shares of Halozyme Therapeutics by 3.8% during the fourth quarter. StoneX Group Inc. now owns 3,650 shares of the biopharmaceutical company’s stock worth $246,000 after purchasing an additional 132 shares in the last quarter. Moran Wealth Management LLC increased its position in shares of Halozyme Therapeutics by 0.4% in the fourth quarter. Moran Wealth Management LLC now owns 35,596 shares of the biopharmaceutical company’s stock worth $2,396,000 after purchasing an additional 151 shares during the last quarter. Finally, Coldstream Capital Management Inc. increased its position in shares of Halozyme Therapeutics by 1.9% in the third quarter. Coldstream Capital Management Inc. now owns 8,914 shares of the biopharmaceutical company’s stock worth $654,000 after purchasing an additional 165 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Wall Street Zen raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Morgan Stanley decreased their price target on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a report on Tuesday, May 12th. Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. UBS Group restated a “buy” rating and set a $90.00 price objective on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Finally, Weiss Ratings raised shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, May 12th. Eight equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $81.60.

Insider Buying and Selling at Halozyme Therapeutics

In other news, Director Bernadette Connaughton sold 1,625 shares of the stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $76.71, for a total transaction of $124,653.75. Following the completion of the sale, the director owned 42,044 shares of the company’s stock, valued at approximately $3,225,195.24. This represents a 3.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 1,923 shares of the firm’s stock in a transaction that occurred on Wednesday, July 8th. The stock was sold at an average price of $79.77, for a total transaction of $153,397.71. Following the completion of the transaction, the chief executive officer owned 767,780 shares in the company, valued at $61,245,810.60. This represents a 0.25% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 74,102 shares of company stock worth $5,205,798. 2.50% of the stock is currently owned by insiders.

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $81.93 on Monday. Halozyme Therapeutics, Inc. has a 1-year low of $57.67 and a 1-year high of $82.99. The company has a current ratio of 2.76, a quick ratio of 2.33 and a debt-to-equity ratio of 8.81. The stock has a 50-day moving average of $73.08 and a 200-day moving average of $70.58. The firm has a market cap of $9.72 billion, a PE ratio of 29.47, a price-to-earnings-growth ratio of 0.34 and a beta of 0.84.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.06. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The company had revenue of $376.71 million during the quarter, compared to analysts’ expectations of $358.60 million. During the same period in the prior year, the business posted $1.11 EPS. Halozyme Therapeutics’s quarterly revenue was up 42.2% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. As a group, sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.